Drs. Julie Magarian Blander and Steven Lipkin are award recipients of the 2018 Daedalus Fund for Innovation. This award is given to advance early-stage reserach projects that have significant commercial potential for translation of their discoveries into new and more effective treatments for patients. To read more, click here. Donor gift establishes Friedman Center for Nutrition and Inflammation, an innovative cross-campus center dedicated to improving human health through research in the complex relationship between nutrition, inflammation and the development of disease. To read more, click here. The Jill Roberts Institute has been busy with two studies published this month! From the Iliev Lab, the study "Sensing of Fungi by Gut Immune Cells Can Contribute to Airway Allergic Diseases," was published online on November 29 in Cell Host and MicrobeTo read more, click here. From the Longman Lab, the study, "Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis," was published on December 11 in Immunity. To read more, click here.  The Kenneth Rainin Foundation awarded Dr. Iliyan Iliev and colleagues from Mount Sinai a $250,000 Synergy Award to examine the composition of the fungal community in babies born to mothers with inflammatory bowel disease. To read more, click here. Dr. Randy Longman received the Irma T. Hirschl Career Scientist Award and the New York Crohn’s Foundation Award.    

The Jill Roberts Institute for Research in Inflammatory Bowel Disease

You are here

The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells.

TitleThe soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells.
Publication TypeJournal Article
Year of Publication2016
AuthorsChorny, A, Casas-Recasens, S, Sintes, J, Shan, M, Polentarutti, N, García-Escudero, R, A Walland, C, Yeiser, JR, Cassis, L, Carrillo, J, Puga, I, Cunha, C, Bastos, H, Rodrigues, F, Lacerda, JF, Morais, A, Dieguez-Gonzalez, R, Heeger, PS, Salvatori, G, Carvalho, A, Garcia-Sastre, A, J Blander, M, Mantovani, A, Garlanda, C, Cerutti, A
JournalJ Exp Med
Volume213
Issue10
Pagination2167-85
Date Published2016 Sep 19
ISSN1540-9538
Abstract

Pentraxin 3 (PTX3) is a fluid-phase pattern recognition receptor of the humoral innate immune system with ancestral antibody-like properties but unknown antibody-inducing function. In this study, we found binding of PTX3 to splenic marginal zone (MZ) B cells, an innate-like subset of antibody-producing lymphocytes strategically positioned at the interface between the circulation and the adaptive immune system. PTX3 was released by a subset of neutrophils that surrounded the splenic MZ and expressed an immune activation-related gene signature distinct from that of circulating neutrophils. Binding of PTX3 promoted homeostatic production of IgM and class-switched IgG antibodies to microbial capsular polysaccharides, which decreased in PTX3-deficient mice and humans. In addition, PTX3 increased IgM and IgG production after infection with blood-borne encapsulated bacteria or immunization with bacterial carbohydrates. This immunogenic effect stemmed from the activation of MZ B cells through a neutrophil-regulated pathway that elicited class switching and plasmablast expansion via a combination of T cell-independent and T cell-dependent signals. Thus, PTX3 may bridge the humoral arms of the innate and adaptive immune systems by serving as an endogenous adjuvant for MZ B cells. This property could be harnessed to develop more effective vaccines against encapsulated pathogens.

DOI10.1084/jem.20150282
Alternate JournalJ. Exp. Med.
PubMed ID27621420
PubMed Central IDPMC5030794
Grant ListP01 AI061093 / AI / NIAID NIH HHS / United States
R01 AI057653 / AI / NIAID NIH HHS / United States
U01 AI095613 / AI / NIAID NIH HHS / United States